Adia Nutrition Stock Price, News & Analysis

Adia Nutrition Inc. (OTCQB: ADIA) has announced that its medical subsidiary, Adia Med, has filed to become an in-network provider with TRICARE, a healthcare program serving 9.5 million military-related beneficiaries. The company expects to secure TRICARE provider status by August 31, 2025, accessing a program that disbursed $50.6 billion in medical treatments in FY2019.

Additionally, Adia Med anticipates approval as a United Healthcare provider by August 1, 2025, and has begun submitting its first patient insurance claims. The company offers regenerative treatments including Umbilical Cord Blood Stem Cell therapies, Autologous Hematopoietic Stem Cell Transplantation, and Therapeutic Plasma Exchange at its Winter Park clinic.

Adia Nutrition (OTCQB: ADIA) has partnered with CareCredit to offer patients financing options of up to $25,000 for medical treatments. This strategic move taps into the $48.35 billion U.S. healthcare finance solutions market as of 2023.

The company has transitioned from its previous provider, Cherry, to CareCredit as its primary financing partner. This partnership aims to make Adia's advanced treatments, including stem cell treatments and regenerative protocols, more accessible to patients through flexible payment options.

Adia Nutrition Inc. (OTCQB: ADIA) has announced the grand opening of its first licensed clinic, Adia Med of San Antonio, located in Texas. The clinic, led by Dr. Michele DeLeon, will offer FDA-registered regenerative medicine products including AdiaVita (containing 100 million viable cells and 3 trillion exosomes per unit) and AdiaLink (3.5 trillion exosomes per unit).

The new facility will collaborate with Adia Med of Winter Park on a clinical study investigating regenerative therapies for autism. The company is actively expanding its network through licensing opportunities, marking this opening as a strategic milestone in its growth plan.

Adia Nutrition Inc. (OTCQB: ADIA) is approaching a significant milestone as its medical subsidiary, Adia Med, nears final approval to become an in-network provider with United Healthcare. The anticipated approval, expected by August 1, 2025, will enable insurance coverage for Adia Med's advanced regenerative therapies including Autologous Hematopoietic Stem Cell Transplantation (AHSCT) and Therapeutic Plasma Exchange (TPE).

The company has already initiated its first patient insurance claim through United Healthcare, signaling progress toward integration. This strategic development will expand Adia Med's market reach by making its treatments accessible to United Healthcare's extensive patient network while establishing a scalable reimbursement pathway in the regenerative medicine sector.

Adia Nutrition Inc. (OTCQB: ADIA) has launched a nationwide TV commercial campaign for Adia Vita, its stem cell therapy product, using MNTN's (NYSE: MNTN) Connected TV platform. The product contains an impressive 100 million stem cells and 3 trillion exosomes per dose, positioning itself as a leader in the $15.1 billion global stem cell market.

The campaign aims to encourage patients to discuss Adia Vita with their physicians, highlighting the product's potential in regenerative medicine. The commercial emphasizes that physicians have the legal right to use approved biologic products like umbilical cord stem cells off-label when deemed appropriate for their patients.

Adia Nutrition Inc. (OTCQB: ADIA) is capitalizing on Florida's Senate Bill 1768, which legalizes stem cell therapies for orthopedics, wound repair, and pain management effective July 1, 2025. The company's Adia Med clinic in Winter Park is offering free consultations and inviting the community to explore their advanced regenerative therapies. Operating in the $15.1 billion global stem cell industry, Adia is positioning itself as a support partner for Florida clinics, providing assistance with stem cell trials, research, and procedures. CEO Larry Powalisz emphasizes their commitment to helping clinics implement these therapies with premium support and service. The new legislation requires strict safety and efficacy standards while expanding access to innovative treatments, establishing Florida as a leader in regenerative medicine.

Adia Nutrition (OTCQB: ADIA) has achieved a significant milestone as its Adia Med of Winter Park clinic receives Agency for Health Care Administration (AHCA) approval, enabling insurance coverage acceptance for its treatments. The clinic, which opened in January 2025, specializes in innovative therapies including Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for Multiple Sclerosis and therapeutic plasma exchange (TPE). This approval positions Adia Med to enter the $4.9 trillion healthcare insurance market and makes their cutting-edge regenerative treatments more accessible to patients across Florida. The clinic will now work directly with patients to advocate for insurance coverage of their treatments, potentially reducing financial barriers to advanced medical care.

Adia Nutrition (OTCQB: ADIA) has launched Cherry Payment Plans at its Adia Med clinics, including the flagship location in Winter Park, Florida. The new financing program allows patients to spread treatment costs over monthly installments, making innovative therapies more financially accessible. The initiative was announced by CEO Larry Powalisz and aims to reduce financial barriers to accessing transformative treatments. The Winter Park clinic, which opened in January 2025, is part of Adia Med's expanding clinical network focused on personalized care. Interested patients can learn more about treatment options and financing through the company's website. Additionally, Adia Nutrition is scheduled to present at the Life Sciences Virtual Investor Forum on June 11th, 2025, at 2:00 PM EST.

Adia Nutrition (OTCQB: ADIA) announces expansion of its business model through licensing agreements to meet growing global demand for its regenerative therapies. The company will allow approved clinics worldwide, particularly in the US, Colombia, and Mexico, to operate under the Adia Med brand. Licensed clinics must exclusively source stem cell and exosome products from Adia Labs LLC and maintain Adia Med's quality standards. The program includes access to signature treatments like AdiaVita (100M stem cells, 3T exosomes) and AdiaLink (3.5T exosomes). This strategic move positions Adia Nutrition to capture a larger share of the $15.1B stem cell market while ensuring consistent quality through FDA-registered, cGMP-compliant products.